Baidu
map

Cell子刊:新方法纯化出史上最纯的肝细胞群体

2016-08-31 佚名 生物谷

在一项新的研究中,来自美国南卡罗莱纳医科大学和威斯康星医学院的研究人员发现一种更好的方法纯化利用诱导性多能干细胞(ipsC)制造出的肝细胞。这一发现将有助研究肝脏疾病。相关研究结果于2016年8月25日在线发表在Stem Cell Reports期刊上,论文标题为“Mapping the Cell-Surface N-Glycoproteome of Human Hepatocytes Rev

在一项新的研究中,来自美国南卡罗莱纳医科大学和威斯康星医学院的研究人员发现一种更好的方法纯化利用诱导性多能干细胞(ipsC)制造出的肝细胞。这一发现将有助研究肝脏疾病。相关研究结果于2016年8月25日在线发表在Stem Cell Reports期刊上,论文标题为“Mapping the Cell-Surface N-Glycoproteome of Human Hepatocytes Reveals Markers for Selecting a Homogeneous Population of ipsC-Derived Hepatocytes”。

这种新方法可能促进一种重要的临床目标---通过移植利用自己的干细胞产生的未发生突变的肝细胞来治疗肝脏中存在致病性突变的病人---取得突破。之前的利用干细胞产生肝样细胞(liver-like cell)的研究产生异质性的细胞群体,而且这种细胞群体与病人体内的患病肝脏存在很少的类似性。

传统上抗体被用来识别细胞表面上的成熟特征和纯化相似的细胞。这种方法在干细胞研究中是至关重要的,但是可购买的识别成熟肝细胞的抗体比较少,而且往往识别许多不同类型的细胞。在混合细胞群体中的很多细胞类型具有不同的特征,从而可能会遮盖住潜在的致病性的基因突变。

论文通信作者、南卡罗莱纳医科大学发育生物学家Stephen A. Duncan博士说道,“如果没有一种纯的肝细胞群体,就很难找出这些基因突变导致的相对微妙的差异,但是这些差异在一个人的一生当中起着重要的作用。”

为了不依赖抗体,Duncan和同事们采取一种被称作化学蛋白质组细胞表面捕获(chemoproteomic cell surface capture, CSC)的新技术。标记的细胞要比未标记的细胞具有更加类似的成熟肝细胞特征。未发生分化的多能性干细胞被排除在标记的细胞群体之中。

Duncan说,“这是比较重要的。如果你想要将细胞移植到患有肝脏疾病的病人体内,那么你肯定不想要也将多能性干细胞移植到病人体内,这是因为多能性干细胞会形成畸胎瘤。”

Duncan提醒道,迄今为止,移植利用iPSC产生的干细胞还未准备转化到诊所临床实践当中。但是如今,这种分选同质的肝细胞的技术能够被用来在细胞培养皿中成功地和准确地建立疾病模型和研究疾病。

原始出处

Sunil K. Mallanna, Max A. Cayo, Kirk Twaroski, Rebekah L. Gundry, Stephen A. Duncan.Mapping the Cell-Surface N-Glycoproteome of Human Hepatocytes Reveals Markers for Selecting a Homogeneous Population of ipsC-Derived Hepatocytes.Stem Cell Reports.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959789, encodeId=eb5c1959e89cd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 11 09:44:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903153, encodeId=38831903153f4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 26 01:44:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869530, encodeId=c8a0186953075, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 02 06:44:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863251, encodeId=0bd41863251e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Feb 24 14:44:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716943, encodeId=ebc21e1694392, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Aug 15 09:44:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108936, encodeId=813310893679, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2017-04-11 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959789, encodeId=eb5c1959e89cd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 11 09:44:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903153, encodeId=38831903153f4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 26 01:44:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869530, encodeId=c8a0186953075, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 02 06:44:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863251, encodeId=0bd41863251e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Feb 24 14:44:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716943, encodeId=ebc21e1694392, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Aug 15 09:44:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108936, encodeId=813310893679, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959789, encodeId=eb5c1959e89cd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 11 09:44:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903153, encodeId=38831903153f4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 26 01:44:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869530, encodeId=c8a0186953075, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 02 06:44:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863251, encodeId=0bd41863251e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Feb 24 14:44:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716943, encodeId=ebc21e1694392, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Aug 15 09:44:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108936, encodeId=813310893679, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959789, encodeId=eb5c1959e89cd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 11 09:44:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903153, encodeId=38831903153f4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 26 01:44:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869530, encodeId=c8a0186953075, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 02 06:44:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863251, encodeId=0bd41863251e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Feb 24 14:44:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716943, encodeId=ebc21e1694392, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Aug 15 09:44:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108936, encodeId=813310893679, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2017-02-24 xjy02
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959789, encodeId=eb5c1959e89cd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 11 09:44:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903153, encodeId=38831903153f4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 26 01:44:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869530, encodeId=c8a0186953075, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 02 06:44:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863251, encodeId=0bd41863251e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Feb 24 14:44:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716943, encodeId=ebc21e1694392, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Aug 15 09:44:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108936, encodeId=813310893679, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2017-08-15 xjy13
  6. [GetPortalCommentsPageByObjectIdResponse(id=1959789, encodeId=eb5c1959e89cd, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Apr 11 09:44:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903153, encodeId=38831903153f4, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Thu Jan 26 01:44:00 CST 2017, time=2017-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869530, encodeId=c8a0186953075, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Jan 02 06:44:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863251, encodeId=0bd41863251e6, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Feb 24 14:44:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716943, encodeId=ebc21e1694392, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Aug 15 09:44:00 CST 2017, time=2017-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=108936, encodeId=813310893679, content=学习起来, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Thu Sep 01 13:12:00 CST 2016, time=2016-09-01, status=1, ipAttribution=)]
    2016-09-01 Guoxj3234

    学习起来

    0

相关资讯

药物研发史上里程碑式的进展——科学家可无限制的生产功能性肝细胞

肝脏在人体代谢过程中起着重要的作用。作为消化道的“门卫”,肝脏负责药物的降解,因此成为了最易由于药物过量或滥用而受损的器官。评估药物诱导性肝损伤是研发药物的重要部分,必须对人体干细胞进行研究实验。遗憾的是,人类干细胞的供应很少,仅能从捐赠的器官中分离获得。现在,发表于《肝脏病学杂志 》的一项研究表明,科学家已成功通过人胚胎干细胞和基因功能诱导出大量有功能的肝细胞。“这是药物研发史上一个革

发现氢化珊瑚钙或可防治脂肪肝

随着人们生活水平的提高和膳食的改变,高脂饮食导致的肝细胞脂肪变性发生率急剧升高。日前,西安交通大学刘健康团队发现,采用氢气缓释剂—氢化珊瑚钙可有效防治高脂饮食所致的大鼠脂肪肝;而同样在高脂饮食条件下,阿尔茨海默氏症(AD)转基因小鼠的肝脏脂肪合成显着抑制,并不形成脂肪肝,但显着推进血糖升高和胰岛素抵抗发生。相关研究分别发表在《神经化学杂志》和《生化药理学》。 研究发现,氢化珊瑚钙在体外和在体

Nature:人皮肤细胞可变身功能性肝细胞

再生医学的力量使得科学家们现在能够将皮肤细胞转化为与心脏细胞、胰腺细胞甚至神经元非常相似的细胞。然而,事实证明拯救生命疗法的重要前提条件:获得完全成熟的细胞生成方法比想象中要困难得多。现在,来自Gladstone研究所和加州大学旧金山分校(UCSF)的科学家们取得了一项重大的突破:他们发现了一种方法可将皮肤细胞转化为成熟的、全功能的肝细胞,甚至在移植到模拟肝衰竭的实验室遗传修饰动物体内后也能自身旺

Cell:Hippo通路可能是成熟肝细胞转变干细胞的开关

在美国,每10个人中就有一个人是肝病患者。从目前的诊断和治疗方法来看,有保持水分、用药或器官移植是通常的治疗方法。一群来自哈佛干细胞研究所(Harvard Stem Cell Institute ,HSCI),由Fernando Camargo领导的科学家,日前发现成熟的肝细胞转化为干细胞的方法,他们称未来可通过该方法来治疗肝脏疾病。相关研究发表在Cell杂志上。事实上,去年第二军医大学干细胞与医

Cell Stem Cell:首次在肝脏内将导致肝病的细胞转化为功能性的肝细胞

干细胞研究取得的进展使得在实验室培养皿中能够将病人的皮肤细胞转化为心脏细胞、肾脏细胞和肝细胞等,这就给科学家们提供希望:有朝一日,这些细胞能够替换器官移植用于治疗器官衰竭病人。但是将这些细胞成功地移植到病人的功能衰竭的器官中仍然是一个重要的临床挑战。如今,来自美国加州大学旧金山分校和德国海德堡大学医院的研究人员在小鼠体内证实在肝脏内产生健康的新的肝细胞是可能的,这就使得细胞移植是不必要的。

Baidu
map
Baidu
map
Baidu
map